Market Overview

Biotech Expert Talks Potential M&A Activity, Partnerships And Women's Health

Biotech Expert Talks Potential M&A Activity, Partnerships And Women's Health
Related JUNO
A Survey Of Celgene's M&A Strategy
Benzinga's Top Upgrades, Downgrades For January 18, 2018
Fledgling Biotech Company's Stock Surges (GuruFocus)
Related CELG
Will Johnson & Johnson's Pharma Segment Pull Up Its Q4 Earnings?
A Survey Of Celgene's M&A Strategy
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update (Seeking Alpha)

Benzinga recently had the chance to chat with Jason Napodano, biopharma analyst and consultant, owner of BioNap Consulting and former biotech analyst at Zacks. Below are just a few of the expert’s comments on potential M&A activity and partnerships in the biotech segment in the current market, in addition to a brief comment on women's health.

Potential M&A Activity

When asked about the potential M&A activity in biotech in the current market and macro environment, the analyst explained that biotech companies use each other’s shares as currency.

For instance, if Juno Therapeutics Inc (NASDAQ: JUNO) was down 50 percent from months ago and Celgene Corporation (NASDAQ: CELG) made a deal for 30 percent premium, investors would be disturbed, he expounded.

Related Link: Jason Napodano On His Approach To Biotech & Current Market Conditions

That being said, Napodano noted it is a common misconception that biotech M&A deals are completed during selloffs and bear markets. Quite the opposite: the analyst believes it is more likely for these deals to occur in bull markets.

Partnerships And Biotech

Partnerships are fundamental for biotech companies, especially during development stages. When questioned about them, Napodano said partnerships are more attractive than outright M&A deals, noting that can be particularly beneficial for small companies in terms of funding.

The basic idea here is that “50 percent of something is better than 100 percent of nothing.”

Women’s Health

Finally, the expert was prompted on women's health in general and endometriosis and Neurocrine Biosciences, Inc. (NASDAQ: NBIX) in particular.

Regarding this subject, he commented that endometriosis' current treatments, like Lupron, are actually cancer drugs that aren't specifically designed for endometriosis.

Consequently, Neurocrine can specialize and take advantage of developing a drug specifically designed to treat endometriosis, as opposed to bigger biotech firms that may pass on the opportunity.

Image Credit: Public Domain

Latest Ratings for JUNO

Jan 2018CitigroupDowngradesBuyNeutral
Jan 2018NeedhamInitiates Coverage OnBuy
Nov 2017Leerink SwannMaintainsOutperform

View More Analyst Ratings for JUNO
View the Latest Analyst Ratings

Posted-In: BioNap ConsultingAnalyst Color Biotech Long Ideas Exclusives Analyst Ratings Trading Ideas General Best of Benzinga


Related Articles (CELG + JUNO)

View Comments and Join the Discussion!